Last reviewed · How we verify

Estracty (ESTRAMUSTINE)

Pharmacia And Upjohn · discontinued Small molecule

Estramustine works by attaching an alkyl group to DNA, interfering with cell division and ultimately killing cancer cells.

Estramustine, also known as Estrapharma, is a small molecule alkylating drug. It is used to treat neoplasms of the prostate. Originally developed by, it is currently owned by Pharmacia And Upjohn. The commercial status of Estramustine is off-patent, with no active Orange Book patents. As an off-patent medication, it may be available from generic manufacturers.

At a glance

Generic nameESTRAMUSTINE
SponsorPharmacia And Upjohn
Drug classAlkylating Drug
ModalitySmall molecule
Therapeutic areaOncology
Phasediscontinued

Mechanism of action

Imagine your DNA as a blueprint for your cells. Estramustine disrupts this blueprint by adding an extra piece of information, which confuses the cell and prevents it from growing and dividing. This ultimately leads to the death of the cancer cell.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results